Luminex MAP-based services

Rules-Based Medicine (RBM), an IQVIA business, has been internally developing and validating assays utilizing the Luminex multi-analyte profile (MAP) technology for the past 25 years. This bead-based platform enables RBM to simultaneously detect and quantify up to 200+ targets in a single sample. Our comprehensive menu of quantitative, multiplex immunoassays enables you to measure multiple clinically relevant proteins using a small sample volume. Our scientists also developed and validated multiplex, MAP-based profiles for various therapeutic areas.

The RBM MAP technology combines the sensitivity and dynamic range of microsphere-based immuno-multiplexing with the precision and reliability of automated liquid handling to deliver high-quality, cost-effective immunoassay measurements. For MAP-based services, serum and plasma are the most common sample types, but we can also analyze other biological fluids including cerebrospinal fluid (CSF), urine, tissue culture supernatants, bronchoalveolar lavage, synovial fluid, tissue extracts, tears, and skin washings.

Our Luminex-based MAPs include:

• Cytokine MAP A

  • 16 biomarkers focused on immune-signaling and cytokine profiling, including interleukins, TNFs

• Cytokine MAP B

  • 12 biomarkers focused on immune-signaling and cytokines, including interleukins, matrix metalloproteinase and VEGF

• Discovery MAP

  • This MAP of exploratory biomarkers includes >200 markers such as interleukins, cancer antigens, CDs, chemokines, endocrine markers, macrophage inflammatory proteins, matrix metalloproteinase, TNFs, and VEGF 

• Human MAP

  • >75 biomarkers with broad coverage across general human biology and disease

• Inflammation MAP

  • >50 biomarkers focused on inflammatory and immune responses, targeting cytokines, chemokines and acute-phase proteins

• Kidney MAP

  • 9 biomarkers focused on renal injury and disease, including creatinine and cystatin-C

Or choose the specific analytes of interest and let us build a Custom MAP:

• Custom profile builder

We also offer a suite of validated biomarkers for idiopathic pulmonary fibrosis (IPF):

• IPF biomarkers developed with the PROLIFIC consortium

  • Epithelial damage (CA 125, CYFRA 21-1, SP-D, CA-19-9, KL-6),
  • Fibrosis (MMP-7, Tenascin C),
  • Inflammation (CCL18, CXCL13, slCAM1),
  • Thrombosis (PAI-1).

Review our bibliography to see how our assays have supported hundreds of peer-reviewed papers.